Compare Stocks: XGN, GMRS, FLGT, and SRTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGT Fulgent Genetics	$19.84 +0.9%	$19.71	$13.46 ▼ $31.04	$545.69M	0.93	428,072 shs	151,330 shs
GMRS GMR Solutions	$13.51 +0.7%	$13.51	$10.26 ▼ $15.98	$729.81M	N/A	814,735 shs	300,416 shs
SRTA Strata Critical Medical	$5.33 -0.8%	$5.50	$3.85 ▼ $6.50	$471.10M	2.26	967,821 shs	459,965 shs
XGN Exagen	$7.58 +0.5%	$5.73	$2.59 ▼ $12.23	$183.66M	2.1	401,159 shs	107,529 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGT Fulgent Genetics	-1.95%	-1.50%	+5.93%	+2.61%	-10.76%
GMRS GMR Solutions	+3.80%	+6.36%	+6.62%	+22.21%	+1,336,999,900.00%
SRTA Strata Critical Medical	-0.37%	-12.97%	-3.59%	-7.25%	+536,999,900.00%
XGN Exagen	+0.40%	+0.27%	+16.90%	+75.76%	-22.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGT Fulgent Genetics	$19.84 +0.9%	$19.71	$13.46 ▼ $31.04	$545.69M	0.93	428,072 shs	151,330 shs
GMRS GMR Solutions	$13.51 +0.7%	$13.51	$10.26 ▼ $15.98	$729.81M	N/A	814,735 shs	300,416 shs
SRTA Strata Critical Medical	$5.33 -0.8%	$5.50	$3.85 ▼ $6.50	$471.10M	2.26	967,821 shs	459,965 shs
XGN Exagen	$7.58 +0.5%	$5.73	$2.59 ▼ $12.23	$183.66M	2.1	401,159 shs	107,529 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGT Fulgent Genetics	-1.95%	-1.50%	+5.93%	+2.61%	-10.76%
GMRS GMR Solutions	+3.80%	+6.36%	+6.62%	+22.21%	+1,336,999,900.00%
SRTA Strata Critical Medical	-0.37%	-12.97%	-3.59%	-7.25%	+536,999,900.00%
XGN Exagen	+0.40%	+0.27%	+16.90%	+75.76%	-22.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGT Fulgent Genetics	2.00	Hold	$27.50	38.64% Upside
GMRS GMR Solutions	2.70	Moderate Buy	$18.67	38.17% Upside
SRTA Strata Critical Medical	2.75	Moderate Buy	$8.00	50.23% Upside
XGN Exagen	2.89	Moderate Buy	$9.63	26.98% Upside

Current Analyst Ratings Breakdown

Latest XGN, GMRS, FLGT, and SRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	FLGT Fulgent Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	GMRS GMR Solutions	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$30.00
8/14/2026	GMRS GMR Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/7/2026	XGN Exagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	SRTA Strata Critical Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/5/2026	XGN Exagen	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/5/2026	XGN Exagen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $12.00
8/5/2026	XGN Exagen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/4/2026	FLGT Fulgent Genetics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$15.00 ➝ $19.00
7/6/2026	FLGT Fulgent Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	XGN Exagen	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGT Fulgent Genetics	$322.67M	1.69	N/A	N/A	$36.20 per share	0.55
GMRS GMR Solutions	N/A	N/A	N/A	N/A	$14.61 per share	N/A
SRTA Strata Critical Medical	$197.14M	2.39	N/A	N/A	$3.16 per share	1.69
XGN Exagen	$66.57M	2.76	N/A	N/A	$0.50 per share	15.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGT Fulgent Genetics	-$60.51M	-$2.82	N/A	N/A	N/A	-26.05%	-4.93%	-4.50%	11/6/2026 (Estimated)
GMRS GMR Solutions	N/A	-$1.56	N/A	8.72	0.29	N/A	N/A	N/A	N/A
SRTA Strata Critical Medical	$41.35M	-$0.04	N/A	N/A	N/A	15.71%	-2.97%	-2.54%	N/A
XGN Exagen	-$19.95M	-$0.81	N/A	N/A	N/A	-26.61%	-104.46%	-28.93%	11/3/2026 (Estimated)

Latest XGN, GMRS, FLGT, and SRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	GMRS GMR Solutions	$0.38	-$1.84	-$2.22	-$1.84	N/A	$1.49 billion
8/4/2026	Q2 2026	XGN Exagen	-$0.1914	-$0.13	+$0.0614	-$0.13	$17.80 million	$19.94 million
7/30/2026	Q2 2026	FLGT Fulgent Genetics	-$0.46	-$0.58	-$0.12	-$1.05	$94.00 million	$85.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGT Fulgent Genetics	N/A	N/A	N/A	N/A	N/A
GMRS GMR Solutions	N/A	N/A	N/A	N/A	N/A
SRTA Strata Critical Medical	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGT Fulgent Genetics	N/A	6.34	6.34
GMRS GMR Solutions	5.50	2.01	2.01
SRTA Strata Critical Medical	N/A	2.64	2.64
XGN Exagen	1.96	3.18	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGT Fulgent Genetics	48.06%
GMRS GMR Solutions	N/A
SRTA Strata Critical Medical	47.36%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
FLGT Fulgent Genetics	36.18%
GMRS GMR Solutions	N/A
SRTA Strata Critical Medical	15.50%
XGN Exagen	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGT Fulgent Genetics	1,315	27.51 million	17.56 million	Optionable
GMRS GMR Solutions	N/A	54.02 million	N/A	N/A
SRTA Strata Critical Medical	130	88.47 million	74.76 million	N/A
XGN Exagen	220	24.23 million	21.71 million	Optionable

XGN, GMRS, FLGT, and SRTA Headlines

Recent News About These Companies

Man Group plc Takes $778,000 Position in Exagen Inc. $XGN

September 4 at 4:40 AM | marketbeat.com

Flputnam Investment Management Co. Acquires New Position in Exagen Inc. $XGN

August 31, 2026 | marketbeat.com

Exagen Inc. (NASDAQ:XGN) Receives Average Rating of "Moderate Buy" from Analysts

August 27, 2026 | americanbankingnews.com

Exagen Inc. (NASDAQ:XGN) Given Average Rating of "Moderate Buy" by Brokerages

August 27, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN

August 18, 2026 | marketbeat.com

Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN

August 18, 2026 | marketbeat.com

Exagen (XGN) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock

August 5, 2026 | marketbeat.com

Exagen: The Path To Profitability Just Became More Credible

August 5, 2026 | seekingalpha.com

Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability

August 4, 2026 | finance.yahoo.com

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Exagen Inc. Reports Second Quarter 2026 Financial Results

August 4, 2026 | markets.businessinsider.com

Exagen reports record second-quarter 2026 revenue and raises full-year guidance

August 4, 2026 | msn.com

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2026 | zacks.com

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

August 4, 2026 | quiverquant.comQ

Exagen reports record Q2 revenue of $19.9 million

August 4, 2026 | quiverquant.comQ

Exagen Inc. to Participate in Upcoming Investor Conference

July 28, 2026 | globenewswire.com

Exagen: A Small Diagnostics Company Approaching An Inflection Point

July 23, 2026 | seekingalpha.com

Exagen to Announce Second Quarter Financial Results on August 4, 2026

July 21, 2026 | markets.businessinsider.com

Exagen Shareholders Approve Directors, Auditor and Pay Package

June 9, 2026 | tipranks.com

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

June 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, GMRS, FLGT, and SRTA Company Descriptions

Fulgent Genetics NASDAQ:FLGT

$19.84 +0.19 (+0.96%)

As of 03:57 PM Eastern

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

GMR Solutions NYSE:GMRS

$13.51 +0.10 (+0.75%)

As of 03:52 PM Eastern

GMR Solutions Inc. is a provider of emergency medical services delivering EMS and other essential out-of-hospital care in rural and urban communities. GMR Solutions Inc. is based in Lewisville, Texas.

Strata Critical Medical NASDAQ:SRTA

$5.32 -0.05 (-0.84%)

As of 03:57 PM Eastern

Blade Air Mobility, Inc. provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.

Exagen NASDAQ:XGN

$7.58 +0.04 (+0.53%)

As of 03:57 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XGN, GMRS, FLGT, and SRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XGN, GMRS, FLGT, and SRTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XGN, GMRS, FLGT, and SRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, GMRS, FLGT, and SRTA Company Descriptions

Fulgent Genetics NASDAQ:FLGT

GMR Solutions NYSE:GMRS

Strata Critical Medical NASDAQ:SRTA

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XGN, GMRS, FLGT, and SRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XGN, GMRS, FLGT, and SRTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XGN, GMRS, FLGT, and SRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, GMRS, FLGT, and SRTA Company Descriptions

Fulgent Genetics NASDAQ:FLGT

GMR Solutions NYSE:GMRS

Strata Critical Medical NASDAQ:SRTA

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools